{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:45:21Z","timestamp":1762530321464,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.adro.2021.100882","type":"journal-article","created":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T01:06:55Z","timestamp":1640480815000},"page":"100882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates"],"prefix":"10.1016","volume":"7","author":[{"given":"Zsolt","family":"Szak\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorgen","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelli","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsombor","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-866X","authenticated-orcid":false,"given":"Szabolcs","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-487X","authenticated-orcid":false,"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anett","family":"Balik\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2021.100882_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.adro.2021.100882_bib0002","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2021.100882_bib0003","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/10428194.2017.1375107","article-title":"Anti-CD123 chimeric antigen receptor T-cells (CART): An evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Review","volume":"59","author":"Cummins","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.adro.2021.100882_bib0004","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/028418601750444231","article-title":"Pattern of malignant lymphoma in the United Arab Emirates\u2014A histopathologic and immunologic study in 208 native patients","volume":"40","author":"Castella","year":"2001","journal-title":"Acta Oncol"},{"issue":"suppl 2","key":"10.1016\/j.adro.2021.100882_bib0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.adro.2021.100882_bib0006","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-Hodgkin lymphoma: Diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.adro.2021.100882_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40364-017-0088-5","article-title":"Diagnosis and treatment of CD20 negative B cell lymphomas","volume":"5","author":"Katchi","year":"2017","journal-title":"Biomark Res"},{"key":"10.1016\/j.adro.2021.100882_bib0008","doi-asserted-by":"crossref","unstructured":"Illidge TM. Radioimmunotherapy of lymphoma: A treatment approach ahead of its time or past its sell-by date? 2010;28:2944-2946.","DOI":"10.1200\/JCO.2009.26.8748"},{"key":"10.1016\/j.adro.2021.100882_bib0009","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma","volume":"2","author":"Grillo-L\u00f3pez","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.adro.2021.100882_bib0011","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14712598.2018.1484105","article-title":"Successful translation and future prospects of TALEN editing for leukemia patients. Editorial","volume":"18","author":"Werner Sunderland","year":"2018","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.adro.2021.100882_bib0012","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0013","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0014","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2021.100882_bib0015","doi-asserted-by":"crossref","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et\u00a0al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2015;26(suppl 5):v116-v125.","DOI":"10.1093\/annonc\/mdv304"},{"key":"10.1016\/j.adro.2021.100882_bib0016","doi-asserted-by":"crossref","unstructured":"Zucca E, Arcaini L, Buske C, et\u00a0al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020;31:17-29.","DOI":"10.1016\/j.annonc.2019.10.010"},{"issue":"suppl 4","key":"10.1016\/j.adro.2021.100882_bib0017","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"year":"2001","series-title":"World Health Organization Classification of tumours: Pathology & genetics: Tumours of haematopoietic and lymphoid tissues","author":"Jaffe","key":"10.1016\/j.adro.2021.100882_bib0021"},{"year":"2008","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","key":"10.1016\/j.adro.2021.100882_bib0022"},{"key":"10.1016\/j.adro.2021.100882_bib0023","first-page":"1862","article-title":"Report of the Committee on Hodgkin's disease staging procedures","volume":"31","author":"Rosenberg","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.adro.2021.100882_bib0024","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2015.10.009","article-title":"Radioimmunotherapy and autologous stem-cell transplantation in the treatment of B-cell non-Hodgkin lymphoma","volume":"46","author":"Shimoni","year":"2016","journal-title":"Sem Nucl Med"},{"key":"10.1016\/j.adro.2021.100882_bib0027","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0028","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12695","article-title":"Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study","volume":"164","author":"Ibatici","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.adro.2021.100882_bib0029","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjh.15712","article-title":"Radioimmunotherapy (RIT) for follicular lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry","volume":"184","author":"Hohloch","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.adro.2021.100882_bib0030","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00277-014-2145-6","article-title":"Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life","volume":"93","author":"Andrade-Campos","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.adro.2021.100882_bib0031","unstructured":"U.S. Food and Drug administration. Clinical trial endpoints for the approval of cancer drugs and biologics: Guidance for industry. Available at: https:\/\/www.fda.gov\/media\/71195\/download. Accessed January 22, 2021"},{"key":"10.1016\/j.adro.2021.100882_bib0032","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdm560","article-title":"A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients","volume":"19","author":"Zinzani","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2021.100882_bib0033","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/1078-0432.CCR-10-0162","article-title":"Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients","volume":"16","author":"Zinzani","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2021.100882_bib0034","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1038\/bcj.2016.29","article-title":"Short-course R-CHOP followed by (90)Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results","volume":"6","author":"Stefoni","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.adro.2021.100882_bib0035","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2021.100882_bib0036","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2015.02.025","article-title":"Patients older than 65 years with non-Hodgkin lymphoma are suitable for treatment with (90)Yttrium-ibritumumab tiuxetan: A single-institution experience","volume":"15","author":"Andrade-Campos","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.adro.2021.100882_bib0037","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109421002402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109421002402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:40:16Z","timestamp":1762530016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109421002402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2452109421002402"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2021.100882","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2021.100882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100882"}}